Please ensure Javascript is enabled for purposes of website accessibility
Dan Carroll

Dan Carroll


Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Recent articles

The 5 Fastest-Growing Countries in the World

High-growth economics has helped China emerge as the world's largest economy. Can these five risers follow in its footsteps?

Is Mylan's Lively Third Quarter the Start of Something Special?

Mylan posts Street-beating top and bottom lines behind strong growth in Q3 -- and successfully completing its agreement to purchase a portion of Abbott Labs' generics business could lead to more success ahead.

Zimmer Holdings, Inc. Stays Ahead with a Healthy Third Quarter

As all eyes look forward to the Biomet deal completion, Zimmer quietly inks strong growth from its reconstructive division and from international sales

The 5 Richest States in America

Residents of these five chart-toppers out-earn their peers nationwide, but will these states' economies keep up?

Singapore skyline

The 5 Richest Countries in the World

These five nations have overcome the recession and prospered. But what makes them wealthy while other countries struggle?

The 3 Best Stocks to Invest in Health Insurance

Health insurance stocks have provided big rewards in 2014, but WellPoint, Centene, and UnitedHealth are building long-term windfalls for investors

3 Best Stocks to Invest in Pharma

AbbVie, Novo Nordisk, and Johnson & Johnson are three top healthcare stocks poised to delight investors for years to come

3 Reasons Edwards Lifesciences Corp.'s Stock Could Fall

Though the Sapien valve has powered Edwards's shares to huge gains in 2014, competition is lurking to knock off this market leader.

3 Reasons Zimmer Holdings Inc.'s Stock Could Rise

Zimmer Holdings has underperformed its top orthopedic device competitors year to date, but this medical device leader could be poised for a big rebound in the years to come

3 Reasons Mylan Inc Stock Could Rise

Mylan has underperformed against other leading generic drug stocks in 2014, but that could change in the near future

Visa Sinks the Dow Jones

Pandora also dives on earnings worries in a downbeat end to the week for investors.

Why Universal Health Services, Inc. Stock Jumped

Strong top-line Q2 results and a full-year earnings boost help Universal's stock rally

Why AcelRx Pharmaceuticals Inc Stock Boomed

Following a confirmation of its PDUFA date, AcelRx reeled in gains as regulatory approval looks likely

Why Under Armour, Nokia, and Trulia Are Today's 3 Best Stocks

Earnings season pushes UA and Nokia higher on a slow day for the market.

Pfizer's Incoming Patent Cliff

Pfizer's loss of Lipitor's patent in 2012 slammed this top pharma stock. Will losses of Lyrica and other top drugs in coming years offer a repeat performance?

Why Puma Biotechnology, Inc. Stock Receded Today

After yesterday's ridiculous run-up, Puma investors took profits and pulled back from this blooming biotech

Why Spectranetics Corporation Stock Surged Today

Shares of this medical device maker shot up by more than 10% early after a big FDA approval

Caterpillar's Stock Crumbles as the Dow Fights for Gains

Earnings season wallops this industrial leader, while General Motors also is hammered by its quarterly results.

Why Organovo Holdings Inc Stock Bulked Up Today

A partnership with Johnson & Johnson exploring the company's bio-printed tissue in drug discovery leads to a big pop in shares

Why Hawaiian Holdings, Talisman Energy, and SouFun Holdings are Today's 3 Best Stocks

Earnings season pushed on and helped Hawaiian to a big gain, while Talisman roared higher on acquisitions speculation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.